LEVERKUSEN, Germany (Reuters) – Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($ 7 billion).
The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.
Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.
(Reporting by Frank Siebelt; Writing by Ludwig Burger)
Health News Headlines – Yahoo! News
Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
This article
Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
can be opened in url
http://stylenewster.blogspot.com/2012/11/bayer-5-key-drugs-to-have-combined-peak.html
Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro
